Introduction {#s1}
============

Fish oils, derived from cold water oily fish like albacore tuna and salmon, are high in omega-3 poly-unsaturated fatty acids (n-3 PUFAs), mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are believed to have many health benefits [@pone.0090425-Deckelbaum1]--[@pone.0090425-Amminger1]. N-3 PUFAs and fish oil, the major dietary source of n-3 PUFA have been extensively studied as dietary supplements suggesting beneficial effects for the treatment of inflammation [@pone.0090425-KiecoltGlaser1]--[@pone.0090425-KiecoltGlaser2], macular degeneration [@pone.0090425-Ho1], [@pone.0090425-Tuo1], Alzheimer\'s disease (AD) [@pone.0090425-Hooijmans1], [@pone.0090425-Jicha1], Parkinson\'s disease (PD) [@pone.0090425-Bousquet1]--[@pone.0090425-Lesperance1] depression [@pone.0090425-KiecoltGlaser2], [@pone.0090425-Lesperance1], [@pone.0090425-Logan1] and anxiety disorders [@pone.0090425-KiecoltGlaser2], [@pone.0090425-Ross1]. Optimum maintenance of the synaptosome, brain cell functions, and general health of human central nervous system are potentially facilitated by n-3 PUFA [@pone.0090425-Brenna1]--[@pone.0090425-Duffy1].

Despite of the wide implications of n-3 PUFA on the brain functions, clinical efforts investigating the efficacy of n-3 PUFAs and in that matter, the fish oil as dietary supplements for the treatment of psychiatric diseases have yet met with mixed results. Two separate clinical trials on Alzheimer\'s patients and Parkinson\'s patients supplemented by n-3 PUFA enriched diets failed to deliver a robust outcome. The trials found n-3 PUFA effective only if it was administered during the early onset of the AD [@pone.0090425-Jicha1]; in treating PD, its efficacy was restricted to mitigating the depression syndromes only [@pone.0090425-daSilva1]. N-3 PUFAs demonstrated significant positive impact on the major depressive episodes with anxiety co-morbidity [@pone.0090425-KiecoltGlaser2], [@pone.0090425-Lesperance1]; however, the supplement\'s efficacy on the heterogeneous disease profile (with and without comorbid anxiety) was marginal [@pone.0090425-Lesperance1]. A pilot trial offering n-3 PUFA supplementation to patients immediately after life-threatening incidents resulted in reduced post traumatic syndromes [@pone.0090425-Matsuoka1].

A number of clinical, epidemiological, and laboratory studies linked the health benefits of n-3 PUFA to various dietary compositions, including EPA alone [@pone.0090425-Ross2], [@pone.0090425-Martins1], the EPA:DHA ratio [@pone.0090425-Freeman1], the arachidonic acid (AA):EPA ratio [@pone.0090425-Adams1], [@pone.0090425-Conklin1] the AA: alpha-linolenic acid (ALA) ratio [@pone.0090425-Lucas1] and the overall n-3 PUFA; n-6 PUFA ratio [@pone.0090425-Simopoulos1]. Consequently, the appropriate dietary composition is still a subject of ongoing investigation.

Researchers have been using rodent models for decades to evaluate the efficacy of fish oil as the dietary supplement. Justifying the model, studies reported the increased levels of EPA and DHA accompanied by decreased AA in the brain tissues of rats fed on fish oil enriched diets [@pone.0090425-Bourre1], [@pone.0090425-Bourre2]. The n-3 PUFA enriched diet helped balancing behavioral plasticity [@pone.0090425-Bhatia1], improved cognitive function [@pone.0090425-Hooijmans1] and working memory [@pone.0090425-Chung1], enhanced neuroprotection [@pone.0090425-Bousquet2], [@pone.0090425-Lim1] and reduced anxiety and depression-like traits [@pone.0090425-Hennebelle1], [@pone.0090425-Ferraz1] *in vitro*. High throughput genomic studies evaluating the effects of fish oil on the rodent brain identified genes involved in ion channels, neuronal function, signal transduction, synaptic plasticity, cytoskeleton and membrane association, and energy metabolism [@pone.0090425-BarceloCoblijn1]--[@pone.0090425-Puskas1].

The comprehension of the underlying molecular mechanism is potentially critical to understand the effect of the fish oil on neuronal activities. Toward this goal, we studied the effects of high dietary intake of fish oil on the genomic regulations in the mouse brain, and characterized the potentially associated molecular events focused on the nervous system and neurofunctions. The effects of FD on the genes relevant to neurogenesis are of particular interest in the context of the recent study manifesting n-3PUFA as the mediators in generating new neuronal cells [@pone.0090425-Yon1].

Materials and Methods {#s2}
=====================

2.1 Ethics statement {#s2a}
--------------------

Research was conducted in compliance with the Animal Welfare Act, and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals (NRC 2011) in facilities that are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, International. The protocol was approved by the IACUC committee of Walter Reed Army Institute of Research, Silver Spring, MD.

2.2 Diet types and mouse handling {#s2b}
---------------------------------

The percentage of the fish oil in the customized FD was restricted to 16% to maintain the food pellet structure consistent with that of SD (Certified Rodent Diet 5002\*, Purina LabDiet, MA). Thus, the external appearance and texture of FD and SD appeared similar. Solid food pellets helped maintaining the tidiness of the cages; hence, the cages occupied by FD- or SD-fed mice followed the same schedule of regular lab handling, precluding any concerns associated with psychological bias due to the handling with variable frequency [@pone.0090425-Balcombe1]. Possible bias due to the rodents\' potential favoring of particular food textures was further averted by introducing the two diets with similar textures.

Briefly, these two diets were similarly supplemented by proteins (FD: 18.3%, SD: 20.7%, both by weight), carbohydrates (FD: 53.8%, SD: 51.8%, by weight) and crude fibers (FD: 4%, SD: 4.3%, by weight); vitamins and minerals were also supplemented proportionately including vitamin E (FD: 90 IU/kg; SD: 65 IU/kg). The different supplements of fat (FD: 16%; SD: 5.5%, both by weight), primarily the higher n-3 PUFA supplements in FD (FD: 4.70%; SD: 0.20%, by weight) outlined the major difference between FD and SD. The n-6 PUFA supplements were marginally lower in FD (FD: 0.66%; SD: 1.22%, by weight). Overall caloric contributions from the two diets were comparable (FD: 4.2 Kcal/g; SD: 4.07 Kcal/g) ([Table 1](#pone-0090425-t001){ref-type="table"}). To maintain the food quality across the study duration and to minimize the oxidative damage to n-3 PUFA, freshly prepared food was purchased every two months and stored at 4°C in sealed bags and the food chambers were replenished daily with fresh supplies.

10.1371/journal.pone.0090425.t001

###### Compositions of the primary nutrients and n-3 PUFA and n-6 PUFA in two diets of interest.

![](pone.0090425.t001){#pone-0090425-t001-1}

                                               Fish diet (FD)   Standard diet (SD)               
  --------------------------------- --------- ---------------- -------------------- ------------ -------
  **Primary Nutrients**                                                                          
  **Protein**                                       18.3               17.2             23.9      24.11
  **Carbohydrate**                                  51.8               48.8             53.8      62.67
  **Fat**                                           16.0               33.9             5.7       13.22
  ***Kcal/g***                                   ***4.2***                           ***4.07***  
  **Polyunsaturated Fatty Acids**                                                                
  **n-3 PUFA**                       **EPA**        2.56                                0.20     
                                     **DHA**        1.73                                         
                                     **ALA**        0.29                                         
  **n-6 PUFA**                       **LA**         0.29                                1.22     
                                     **AA**         0.37                               \<0.01    
  ***n-3 PUFA∶n-6 PUFA***                        ***7∶1***                           ***1∶6***   
  ***EPA∶DHA***                                 ***1.5∶1***                           ***0***    

The composition of protein, carbohydrate, and fat present in the fish oil enriched diet (FD) and standard diet (SD). The percent fraction by the weight and the calories offered by each diet type is presented. Total calories (Kcal/g) offered by each diet type is noted. The percentage fractions of three n-3 PUFA (EPA, DHA, and ALA) and two n-6 PUFA (AA and LA) are reported.

In designing the assay, we refrained from adjusting any potential shortcomings of the fish oil. For instance FD diet contained 0.3% linoleic acid (LA), whose scale of representation in rodent diets has long been a subject of investigation [@pone.0090425-Bourre3], [@pone.0090425-Cunnane1]; of note the nearly equi-caloric control diet contained 1.22% LA ([Table 1](#pone-0090425-t001){ref-type="table"}), as per the recommendation [@pone.0090425-Bourre3]. Hereby, our result highlighted the diet-induced molecular events potentially explaining the suggested benefits or the adverse effects of fish oil on the brain.

C57BL/6J male mice were purchased from Jackson Laboratory (Bar Harbor, ME) at the age of three weeks, singly housed and immediately introduced to either SD or FD. Mice had free access to their respective diets and standard lab-supplied liquids for next five months (∼20 weeks).

2.3 Collection of hemibrains and RNA isolation {#s2c}
----------------------------------------------

Following the euthanization of the mice by cervical dislocation the brains were removed from their crania. After the mid-sagittal section, the hemibrains were collected by a highly trained professional experienced with this procedure, who was kept blinded from the animal identities during the dissection period. The dissected brain sections were snap-frozen, saved in individually labeled tubes, and transferred to the freezer at the end of the day. The entire process starting with the brain removal from the skull to the snap-freezing of the last brain region took less than 20 minutes as described in our earlier report [@pone.0090425-Hammamieh1].

On the day of nucleic acid isolation, organs were weighed before thawing and the appropriate amounts of Trizol™ (Invitrogen, NY) were added. RNA was isolated from the Trizol™ suspensions as per the manufacturer\'s guidelines. Briefly, the hemibrain was homogenized using the TissueLyser system (Qiagen, MD), phase separated with vigorous agitation, and the aqueous phase was collected. Serial alcohol-based precipitations and washes were performed on the aqueous phase to obtain RNA. The isolated nucleic acids were quantified and qualified using the Agilent BioAnalyzer as reported earlier [@pone.0090425-Hammamieh2].

2.4 High throughput transcriptomic expression analysis {#s2d}
------------------------------------------------------

The dual dye microarray was carried out using the Whole Mouse Genome Microarray Kit (Agilent Technologies, Inc.) following the vendor\'s protocol. 200--2000 ng of purified RNA was labeled with Cy-5 dyes and the reference RNA (Agilent, CA) with Cy-3 dyes (N = 4 from FD-fed mice and N = 3 from SD-fed mice. One SD sample was misplaced). The samples were simultaneously hybridized to Agilent 4×44k slides (platform number: 14868) and incubated for 17 h at 55°C. After overnight hybridization, slides were processed in a series of washes. The slides were scanned using an Agilent DNA microarray scanner and the features were extracted using the default setting of the Feature Extraction software (Feature Extraction software v.10.7, Agilent, CA).

2.5 Data filtering and process normalization {#s2e}
--------------------------------------------

GeneSpring v.10.1 (Agilent Technologies, Inc., CA) was used to carry out the preliminary data filtration and statistical analysis. Each chip was subjected to intra-chip normalization using the locally weighted scatter-plot smoothing method (LOWESS) [@pone.0090425-Berger1]. Genes were identified that were differently expressed between the hemibrains of mice fed on FD vs. SD based on ±1.5 fold change cut-off with FDR\<0.05.

The microarray data was submitted to the Gene Expression Omnibus (GEO). This can be searched using the Platform ID: GPL7202, Series: GSE46933.

2.6 Cluster and functional analysis {#s2f}
-----------------------------------

GeneSpring v.10.1 (Agilent Technologies, Inc., CA) was used to perform two-dimensional hierarchal clustering using Pearson correlation algorithm ([Figure 1](#pone-0090425-g001){ref-type="fig"}).

![Cluster view (heatmap) of 1,142 genes differentially expressed between the mice fed with fish oil enriched diet (FD) vs. standard lab diet (SD).\
These genes are identified using a cut-off of ±1.5 fold changes between the mice with FD vs. SD, with FDR\<0.05, and clustered using Pearson correlation algorithm. The color scale of the fold change (log~1.5~ (FD-/SD-fed mice) is noted at the bottom right of the figure. The first three columns from left represent the genomic expressions of 4 animals fed on FD and subsequent three columns of 3 animals fed on SD.](pone.0090425.g001){#pone-0090425-g001}

For the gene ontological classification and enrichment analysis, FATIGO^+^ [@pone.0090425-AlShahrour1], MSigDB-Parametric Geneset Enrichment analysis (<http://www.broadinstitute.org/gsea/msigdb/index.jsp>) and GeneCite [@pone.0090425-Hammamieh3] were used. Ingenuity Pathway Analysis (IPA; [www.ingenuity.com](http://www.ingenuity.com)) was used to mine the pathways and networks relevant to the present study.

2.7 Real-time PCR validation of microarray results {#s2g}
--------------------------------------------------

The mRNA microarray results were validated using two platforms. The high throughput real-time PCR was carried out using the RT^2^ Profiler PCR Array System (SABiosciences, MD) on the ABI 7900HT platform (Life Technologies, CA). The PCR was carried out using three biological replicates for each diet. SDS 2.4 software supplied by ABI, CA, was used to compute the changes of threshold cycles (Ct) (*i.e.*, 2 ∧ (−Δ Ct), where Δ Ct = Ct (GOI)−mean (Ct (HKG)); GOI denotes the gene of interest, and HKG denotes the housekeeping gene. In order to eliminate the false positives, the mRNA reads were screened based on two criteria: (i) the controls\' threshold cycles were \>30, and samples\' threshold cycles were \<30 (or vice versa), and (ii) the *p*-values for the fold-changes were either unavailable or relatively high (*p*\>0.05) from the assay backgrounds.

In addition, qPCR of five genes (*NOS1*, *FKBP5*, *MMP9*, *SOD1* and *BDNF*) was carried out using primers purchased from Fisher Scientific, Inc, PA using their Solaris gene expression assay ([Table S1](#pone.0090425.s003){ref-type="supplementary-material"}). The selection of these genes is justified in a brief literature survey ([Table 2](#pone-0090425-t002){ref-type="table"}). Real-time PCR was performed in the HT700 platform (Applied BioSystems, CA) using five technical replicates. The downstream analysis was conducted using the GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and beta-actin housekeeping genes following the protocol described elsewhere [@pone.0090425-Hammamieh2].

10.1371/journal.pone.0090425.t002

###### A brief literature survey of clinical studies associated with the panel of genes validated by qPCR.
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  Gene Name                Trauma                                                                                                                   Cohort                                                                                                                                                                                                                            Major findings                                                                                                                                    Reference
  ----------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  NOS-1                  Depression                           Snap-frozen and paraffin-embedded tissue of anterior cingulate cortex from Caucasian subjects; major depressive disorder, *N* = 5; bipolar disorder, *N* = 7; and control *N* = 12                                                                            Diminished NOS1 in anterior cingulate cortex with depression, possibly by affecting glutamatergic and GABAergic neurotransmission                                                                     [@pone.0090425-Gao1]
                             AD                  European subjects; AD (baseline, *N* = 19; 30 months follow-up, *N* = 95; 60 months follow-up, *N* = 106) and controls (baseline, *N* = 555; 30 months follow-up, *N* = 360; 60 months follow-up, *N* = 285)                                                         Decreased NOS1 expression in concert with degeneration of NOS-I neurons likely results in impaired hippocampal nitrinergic neurotransmission.                                                               [@pone.0090425-Reif1]
                        Schizophrenia                                                              Japanese patient; Postmortem brain samples of 12 schizophrenic patients, *N* = 12; and control, *N* = 15                                                                                                                              Decreased NOS-1 is associated with schizophrenia patients; with stronger correlation for female patient                                                                                  [@pone.0090425-Cui1]
               Schizophrenia/Bi-polar disorder                                                Post mortem brain samples from schizophrenic patients *N* = 26; bipolar patients *N* = 30; and controls, *N* = 29                                                                                                                         Over-expression of specific NOS1 isoforms among the schizophrenia patients, but not among bipolar patients                                                                             [@pone.0090425-Silberberg1]
  MMP9          Traumatic brain injury (TBI)                                                                                 TBI patient, *N* = 7; and control, *N* = 4; all male                                                                                                                                                                    Increased levels of MMP-9/-3 in the ventricular CSF of patients with severe TBI.                                                                                          [@pone.0090425-Grossetete1]
                     Bipolar depression                                                                               Patients with bipolar disorder (*N* = 54); and controls (*N* = 29)                                                                                                                                                                        Increased serum MMP-9 during depression in young patients                                                                                                      [@pone.0090425-Rybakowski1]
                             AD                                                                                                AD patients (*N* = 38); and controls (*N* = 34)                                                                                                                                                               Higher MMP-9/TIMP-1 ratios and lower TIMP-1 levels compared to cognitively healthy individuals.                                                                                    [@pone.0090425-Stomrud1]
                            AD/PD                                                                                  AD patients (*N* = 30); PD patients (*N* = 24); and controls (*N* = 32)                                                                                                                                                Elevated MMP-9 in the plasma of AD patients; but no significant changes of MMP-9 levels in PD cohorts.                                                                                [@pone.0090425-Lorenzl1]
                        Schizophrenia                                                                                    Schizophrenic patients (*N* = 442); and controls (*N* = 558)                                                                                                                                                                        Significant preponderance of −1562 C:T polymorphism in patients                                                                                                   [@pone.0090425-Rybakowski2]
  SOD-1                      AD                                                                 Post-mortem brain samples from AD patient, *N* = 4; and patients diagnosed with Huntington\'s Disease, *N* = 4                                                                                                                                                         Decreased SOD-1 in AD patients\' hippocampus                                                                                                            [@pone.0090425-Somerville1]
                  Down syndrome (DS) and AD                                                                       Post-mortem brain samples; DS, *N* = 9, AD, *N* = 9; and controls, *N* = 9                                                                                                                                        Increased SOD-1 in DS temporal, parietal, and occipital cortex, whereas decreased SOD-1 in the AD temporal cortex                                                                         [@pone.0090425-Gulesserian1]
  BDNF                      PTSD                                                             All women cohort, diagnosed with PTSD, *N* = 17; with PTSD+ childhood physical neglect, *N* = 17; controls, *N* = 15                                                                                                                        Lower plasma BDNF in association with PTSD, and more strongly linked with childhood neglect driven PTSD                                                                             [@pone.0090425-GrassiOliveira1]
                            PTSD                                                                                      Patients with history of trauma, *N* = 34; and controls, *N* = 34                                                                                                                                                          Higher level of serum BDNF levels right after the traumatic events decreasing over time                                                                                         [@pone.0090425-Hauck1]
                      Bipolar disorder                                                                                  UK Caucasian subjects, BD, *N* = 962; and control, *N* = 2100                                                                                                                         No overall influence from the Val66Met polymorphism of BDNF, with a moderate association with the susceptibility to the rapid-cycling subset of the disorder.                                                      [@pone.0090425-Green1]
                      Major depression                                                                               Korean subjects, major depression, *N* = 310 and controls, *N* = 209                                                                                                                                                         Significant association of BDNF with the disease onset among the younger subgroup only                                                                                          [@pone.0090425-Lee2]
                             PD                                                                                                 PD patients, *N* = 453 and controls, *N* = 291                                                                                                                                                                                 Increased PD risk in association with the pesticide exposure                                                                                                       [@pone.0090425-Lin1]
                             AD                                                                            AD patients with rapid cognitive decline, *N* = 12; and slow cognitive decline, *N* = 28                                                                                                                                                       Decreased BDNF serum levels in AD patients with fast cognitive decline                                                                                                 [@pone.0090425-Laske1]
  FKBP5                     PTSD                                                                Nonpsychiatric clinic patients with significant levels of childhood abuse and non--child abuse trauma, N = 900                                                                                               High interaction between four SNPs of the FKBP5 gene (rs9296158, rs3800373, rs1360780, and rs9470080) with severity of child abuse as a predictor of adult PTSD                                                     [@pone.0090425-Binder1]
                            PTSD                            Subjects linkage and association studies of the genetics of cocaine, opioid, and alcohol dependence, and controls; N = 1146 European Americans (EAs) and 1284 African Americans (AAs)               *AA subjects:* Significant association between one SNP (rs9470080) with childhood abuse eliciting PTSD. *EA subjects:* Significant association of PTSD risk with alcohol dependence and childhood adverse experiences interacting with FKBP5 polymorphisms        [@pone.0090425-Xie1]
                     Anxiety/depression                   Patients, newly diagnosed with advanced gastric cancer and supposed to receive first-line chemotherapy, *N* = 130; and control similar patients after two cycles of chemotherapy, *N* = 93                                              Significant association of anxiety with FKBP5 rs9296158, and marginal association with rs9470080 and rs1360780. Marginal association of depression with FKBP5 rs9470080 and rs9296158                                           [@pone.0090425-Kang1]
                      Major depression                                                                            Patients diagnosed with major depression, *N* = 68; and controls, *N* = 87                                                                                                                                              Significant interaction between disease status and FKBP5 risk allele carrier status (minor allele T).                                                                                  [@pone.0090425-Menke1]

Past clinical reports (demography of the cohorts and major findings) associated with five genes (*NOS-1*, *MMP-9*, *SOD-1*, *BDNF* and *FKBP5*) are reported.

Results {#s3}
=======

The diet compositions listed in [Table 1](#pone-0090425-t001){ref-type="table"} revealed relatively comparable supplements of major nutrients and consumable calories derived from FD and SD. The major differences between the two diet types were attributed to the n-3 PUFA and n-6 PUFA supplements ([Table 1](#pone-0090425-t001){ref-type="table"}).

The mice weighing 10--12 grams at the age of three weeks had a 61.2% increase in body weight as a result of consuming SD for five months; thus the average weight became 30.96 grams (% CV = 6.12). During the same five month period, FD-fed mice showed 67.2% increase in body weight; the average weight became 36.6 grams (% CV = 13.17). It was a near significant difference in the change of body weights between the FD- vs. SD-fed mice, with the FD-fed group gaining 18% more in body mass (*p* = 0.06).

Transcriptomic analysis identified 1,142 genes altered between the mice fed on FD vs. SD (6.6% of total genes). The GOI demonstrated ±1.5 fold changes with FDR\<0.05. [Figure 1](#pone-0090425-g001){ref-type="fig"} is a cluster view of these GOI generated using the Pearson correlation algorithm; 659 (58% of GOI) and 483 (42% of GOI) transcripts were elevated and suppressed by FD, respectively. One hundred and fifty two unknown genes with the remaining 990 known genes are documented in [Table S2](#pone.0090425.s004){ref-type="supplementary-material"}. [Figure S1](#pone.0090425.s001){ref-type="supplementary-material"} shows a volcano plot of the same gene set. The entire list is available in the public domain: Gene Expression Omnibus (GEO) and this can be using the Platform ID: GPL7202, Series: GSE46933.

Meeting the objectives of the present study, subsequent convergent functional analysis identified the transcripts linked to the *neurogenesis, neuroviability and neurodegenerative disorders*.

3.1. Biofunction analysis {#s3a}
-------------------------

The 1,142 GOI enriched an ensemble of biofunctions. [Table 3](#pone-0090425-t003){ref-type="table"} reports the top-ranked biofunctions (*p*\<0.0001) that are enriched by at least 50 genes. The complete list of biofunctions is shown in the [Table S3](#pone.0090425.s005){ref-type="supplementary-material"}. We identified four biofunctions pertinent to the present objective: "Neurological disease", "Nervous system development and function", "Inflammatory response" and "Cell death", and these were further classified into subcategories enriched by at least 30 genes. Of note, we found certain enriched pathways, such as "LPS/IL-1 Mediated Inhibition of RXR Function", "Amyotrophic Lateral Sclerosis Signaling" and "Hepatic Fibrosis/Hepatic Stellate Cell Activation"; however, we failed to derive biologically meaningful information from these pathways. Therefore, we focused on exploring the four biofunctional modules identified herein. Together, these four biofunctions enlisted 247 genes (153 up- and 94 down-regulated by FD). The majority of the genes (99 genes, i.e. 40% of the 247 genes) encode the proteins that are located in the plasma membrane. Curating from the Allen Brain Atlas (mouse.brain-map.org) we linked the 20% of these 247 genes to possible brain regions ([Table S4](#pone.0090425.s006){ref-type="supplementary-material"}).

10.1371/journal.pone.0090425.t003

###### Significant biofunctions (p\<0.0001) enriched by more than 50 candidates from the 1,142 genes of interest (GOI).
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  Biofunction Categories                                        p-values         Number of Molecules
  ------------------------------------------------------- --------------------- ---------------------
  Genetic Disorder                                         1.09E-3 to 4.24E-6            432
  Neurological Disease                                     1.01E-3 to 5.69E-5            260
  Movement disorder                                             8.13E-04                 93
  Neuropathy                                                    2.43E-03                 88
  Motor neuron disease                                          1.58E-03                 86
  Progressive motor neuropathy                                  1.98E-03                 85
  Encephalopathy                                                1.79E-03                 85
  Neurodegenerative disorder                                    4.50E-04                 76
  Alzheimer\'s disease                                          1.11E-03                 70
  Parkinson\'s disease                                          1.26E-03                 50
  Spinal cord disorder                                          1.89E-04                 30
  Gastrointestinal Disease                                 1.61E-3 to 1.37E-4            232
  Metabolic Disease                                        1.73E-3 to 2.27E-6            211
  Tissue Development                                       1.04E-3 to 1.79E-7            202
  Immunological Disease                                    1.07E-3 to 9.63E-5            193
  Cellular Growth and Proliferation                        1.61E-3 to 5.90E-5            184
  Cardiovascular Disease                                   1.03E-3 to 8.17E-6            180
  Endocrine System Disorders                               1.73E-3 to 4.57E-5            180
  Cellular Development                                     1.06E-3 to 3.03E-7            179
  Cell-To-Cell Signaling and Interaction                   1.04E-3 to 1.46E-11           176
  Molecular Transport                                      1.01E-3 to 3.48E-6            169
  Hematological Disease                                    1.03E-3 to 1.18E-5            165
  Nervous System Development and Function                  1.04E-3 to 7.83E-7            150
  Neurogenesis                                                  5.91E-06                 73
  Neurological process of cells                                 1.01E-07                 51
  Neurological process of neurons                               7.83E-07                 42
  Neurotransmission                                             2.41E-07                 37
  Synaptic transmission                                         4.98E-07                 35
  Development of brain                                          2.42E-04                 33
  Neurotransmission of nervous tissue                           2.54E-06                 30
  Organismal Development                                   1.73E-3 to 2.23E-5            149
  Cellular Movement                                        1.61E-3 to 7.36E-4            123
  Embryonic Development                                    1.54E-3 to 2.23E-5            118
  Hematological System Development and Function            1.04E-3 to 6.18E-6            112
  Inflammatory Disease                                     1.60E-3 to 2.06E-5            111
  Tissue Morphology                                        1.44E-3 to 3.96E-5            109
  Inflammatory Response                                    3.03E-3 to 6.18E-6            108
  Immune response                                               1.14E-04                 102
  Activation of leukocytes                                      7.25E-05                 50
  Activation of mononuclear leukocytes                          4.61E-05                 39
  Activation of lymphocytes                                     1.49E-04                 36
  Activation of T lymphocytes                                   7.59E-05                 30
  Small Molecule Biochemistry                              1.10E-3 to 2.10E-4            107
  Organ Development                                        2.19E-3 to 2.23E-5            101
  Dermatological Diseases and Conditions                   1.73E-3 to 9.63E-5            98
  Cell Signaling                                           1.01E-3 to 3.48E-6            97
  Cell Death                                               1.25E-3 to 1.79E-7            89
  Apoptosis                                                3.03E03 to 8.95E-4            43
  Killing                                                  7.62E-4 to 3.03E-7            23
  Cytotoxicity                                             3.03E-3 to 7.98E-5            23
  Immune Cell Trafficking                                  1.04E-3 to 6.18E-6            80
  Developmental Disorder                                   1.72E-3 to 2.66E-3            79
  Vitamin and Mineral Metabolism                           1.01E-3 to 4.04E-6            75
  Lipid Metabolism                                         1.06E-3 to 2.24E-4            75
  Behavior                                                 1.17E-3 to 3.19E-5            74
  Skeletal and Muscular Disorders                          1.26E-3 to 5.10E-4            67
  Organismal Injury and Abnormalities                      1.73E-3 to 1.89E-8            65
  Connective Tissue Development and Function               1.27E-3 to 3.76E-5            55
  Cardiovascular System Development and Function           1.73E-3 to 6.54E-5            55
  Skeletal and Muscular System Development and Function    1.58E-3 to 3.76E-5            52

Subcategories enriched by \>30 genes associated with the "neurological diseases", "nervous development and functions", "inflammatory response" and "cell death" are elaborated.

### 3.1.i. Neurological diseases {#s3a1}

Two hundred and sixty genes (22.7% of GOI) were associated with the "neurological diseases" with a range of *p* values from 1.01×10^−3^ to 5.96×10^−5^ ([Table 3](#pone-0090425-t003){ref-type="table"}). In particular, we focused on three diseases: (i) movement disorder (MvD) (93 genes, *p* = 8.13×10^−4^) ([Figure 2A](#pone-0090425-g002){ref-type="fig"}, [Tables 3](#pone-0090425-t003){ref-type="table"} and [4](#pone-0090425-t004){ref-type="table"}), (ii) AD (70 genes, *p* = 1.11×10^−3^) ([Figure 2B](#pone-0090425-g002){ref-type="fig"}, [Tables 3](#pone-0090425-t003){ref-type="table"} and [4](#pone-0090425-t004){ref-type="table"}) and (iii) PD (50 genes, *p* = 1.26×10^−3^) ([Figure 2B](#pone-0090425-g002){ref-type="fig"}, [Tables 3](#pone-0090425-t003){ref-type="table"} and [4](#pone-0090425-t004){ref-type="table"}). The movement disorder was the most enriched candidate on the list. We also selected AD and PD for further discussion in light of the suggested implications of n-3 PUFAs on these particular illnesses [@pone.0090425-Hooijmans1], [@pone.0090425-Jicha1], [@pone.0090425-daSilva1], [@pone.0090425-Clark1]. Together, these three diseases explained approximately 34% of the transcripts linked to "neurological diseases", with 16 common genes among three disease types of interest. In addition, 3 transcripts were shared by MvD and AD, and 14 transcripts by MvD and PD.

![Regulatory networks showing the clusters of differentially regulated genes involved in "neurological diseases".\
The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log~1.5~ (FD-/SD-fed mice) in the FD-fed mice compared to the SD-fed mice (a color scale is at the bottom right corner). The genes are clustered based on their proteins\' cellular locations in the nucleus, cytoplasm, plasma membrane and extracellular space. The genes without the location information are grouped under 'unknown'. [*Figure 2A*](#pone-0090425-g002){ref-type="fig"} depicts "movement disorder", the most enriched disease enlisting 70 genes with *p* = 8.13×10^−4^. [*Figure 2B*](#pone-0090425-g002){ref-type="fig"} depicts two additional diseases frequently linked with n-3 PUFA diets. Alzheimer\'s disease (left panel) and Parkinson\'s disease (right panel) enlist 70 and 50 genes with *p* values of 1.11×10^−3^ and 1.26×10^−3^, respectively.](pone.0090425.g002){#pone-0090425-g002}

10.1371/journal.pone.0090425.t004

###### The genomic candidates associated with three top-ranked neurological diseases: movement disorder (MvD), Alzheimer\'s disease (AD) and Parkinson\'s disease (PD).

![](pone.0090425.t004){#pone-0090425-t004-4}

  Entrez ID    Gene Symbol   Log Ratio   Neurological Disease
  ----------- ------------- ----------- ----------------------
  16521           KCNJ5        1.45               AD
  20660           SORL1        1.32            AD, MvD
  14397          GABRA4        1.27          AD, MvD, PD
  15360          HMGCS2        1.24              MvD
  20508          SLC18A3       1.20              MvD
  108068          GRM2         1.18               AD
  99738           KCNC4        1.17          AD, MvD, PD
  18053           NGFR         1.15               AD
  76829           DOK5         1.13               AD
  214779         ZNF879        1.12            MvD, PD
  12671           CHRM3        1.11          AD, MvD, PD
  108043         CHRNB3        1.11          AD, MvD, PD
  12661           CHL1         1.10               AD
  108073          GRM7         1.05          AD, MvD, PD
  94187          ZNF423        1.05              MvD
  20618           SNCG         1.03            MvD, PD
  68957           PAQR6        1.02            MvD, PD
  17441            MOG         1.01            MvD, PD
  140741          GPR6         1.01              MvD
  110893         SLC8A3        0.98            MvD, PD
  14811          GRIN2A        0.98          AD, MvD, PD
  16504           KCNC3        0.97              MvD
  16772           LAMA1        0.96               AD
  114142          FOXP2        0.96            MvD, PD
  72605           CA10         0.94               AD
  224129          ADCY5        0.92              MvD
  12801           CNR1         0.88          AD, MvD, PD
  26380           ESRRB        0.86               AD
  71137           RFX4         0.85              MvD
  63993          SLC5A7        0.84               AD
  213262          FSTL5        0.83          AD, MvD, PD
  140919         SLC17A6       0.83            MvD, PD
  18213           NTRK3        0.80          AD, MvD, PD
  15567          SLC6A4        0.80            AD, MvD
  16536           KCNQ2        0.78              MvD
  19049          PPP1R1B       0.78              MvD
  12161           BMP6         0.75               AD
  407831         TMEM204       0.74            MvD, PD
  19281           PTPRT        0.73          AD, MvD, PD
  20191           RYR2         0.73               AD
  21834           THRB         0.71            MvD, PD
  226922          KCNQ5        0.69            MvD, PD
  218763         LRRC3B        0.69               AD
  192167          NLGN1        0.68            MvD, PD
  230777         HCRTR1        0.67              MvD
  18610           PDYN         0.67              MvD
  239133          DLEU7        0.66            MvD, PD
  12286          CACNA1A       0.66              MvD
  23859           DLG2         0.64            MvD, PD
  17172           ASCL1        0.64              MvD
  213783         PLEKHG1       0.64               AD
  72844          KCTD17        0.62              MvD
  70357          KCNIP1        0.62              MvD
  20745          SPOCK1        0.60               AD
  13492           DRD5         0.59          AD, MvD, PD
  67703          KIRREL3       0.59               AD
  16493           KCNA5        0.59              MvD
  14169           FGF14        0.56              MvD
  269132         GLT25D2       0.56            MvD, PD
  11550          ADRA1D        0.54          AD, MvD, PD
  18125           NOS1         0.54          AD, MvD, PD
  21955           TNNT1        0.53              MvD
  12950          HAPLN1        0.53               AD
  12289          CACNA1D       0.52          AD, MvD, PD
  16785           RPSA         0.52              MvD
  319924          APBA1        0.51               AD
  269513         NKAIN3        0.50          AD, MvD, PD
  16409           ITGAM        0.49              MvD
  94253           HECW1        0.49               AD
  12265           CIITA        0.49               AD
  11555           ADRB2        0.47            AD, MvD
  14407          GABRG3        0.46          AD, MvD, PD
  14407          GABRG3        0.46              MvD
  58178          SORCS1        0.45               AD
  12411            CBS         0.44               AD
  12336          CAPNS1        0.44              MvD
  12048          BCL2L1        0.44              MvD
  435965          LRP3         0.44               AD
  16597           KLF12        0.43            MvD, PD
  170735          ARR3         0.43              MvD
  14708           GNG7         0.43            MvD, PD
  241494         ZNF385B       0.43            MvD, PD
  16522           KCNJ6        0.41            MvD, PD
  29856           SMTN         0.40              MvD
  231872          AIMP2        0.39            MvD, PD
  56807          SCAMP5        0.39              MvD
  54218          B3GALT4       0.37              MvD
  14680           GNAL         0.36              MvD
  20249            SCD         0.35            AD, MvD
  13033           CTSD         0.35               AD
  19697           RELA         0.34          AD, MvD, PD
  14804           GRID2        0.32            AD, MvD
  18753           PRKCD        0.31               AD
  12799            CNP         0.30          AD, MvD, PD
  17528            MPZ         0.29              MvD
  18019          NFATC2        0.27               AD
  244431          SGCZ         0.25            MvD, PD
  241263         GPR158        0.24               AD
  20655           SOD1         −0.32         AD, MvD, PD
  16439           ITPR2        −0.33              AD
  110796          TSHZ1        −0.34              AD
  26419           MAPK8        −0.35              AD
  110886         GABRA5        −0.37         AD, MvD, PD
  19108           PRKX         −0.37             MvD
  239743          KLHL6        −0.39              AD
  16176           IL1B         −0.44         AD, MvD, PD
  20102           RPS4X        −0.45           MvD, PD
  12292          CACNA1S       −0.47         AD, MvD, PD
  243931          TSHZ3        −0.47              AD
  11813           APOC2        −0.50              AD
  17536           MEIS2        −0.50             MvD
  50790           ACSL4        −0.51              AD
  68272           RBM28        −0.52              AD
  52679           E2F7         −0.55           MvD, PD
  18386           OPRD1        −0.60             MvD
  19366          RAD54L        −0.61             MvD
  13653           EGR1         −0.61             MvD
  319625          GALM         −0.65           MvD, PD
  72519          TMEM55A       −0.67           MvD, PD
  13654           EGR2         −0.69             MvD
  117591         SLC2A9        −0.71              AD
  435726         KCNMB3        −0.79           MvD, PD
  77055           KRT76        −0.81              AD
  21785           TFF2         −0.85           MvD, PD
  14173           FGF2         −0.87           AD, MvD
  12363           CASP4        −0.96              AD
  16153           IL10         −0.97           MvD, PD
  252973          GRHL2        −1.03              AD
  76645          PKD1L2        −1.05           MvD, PD
  21926            TNF         −1.21         AD, MvD, PD
  14686           GNAT2        −1.94             MvD
  19109            PRL         −2.23             MvD

The genes are identified by the Entrez ID and gene symbol. The log ratio indicates the log~1.5~ transformed of the average transcriptomic expression from FD-/SD-fed mice.

FD elevated the expression of a substantial subset of transcripts associated with MvD (76%), AD (58%) and PD (74%). Proteins associated with 45 transcripts representing 48% of MvD associated genes are located in membranes; likewise, 42% (29 transcripts) and 54% (27 transcripts) of the proteins related to AD and PD, respectively, are located in the membranes.

A comprehensive FD-induced elevation was observed among the transcripts associated with the calcium and potassium channels (*CACNA1A*, *CACNA1D*, *KCNMB3*, *KCNQ5*, *KCN1P1*, *KCNC4*, *KCNC3*, *KCNA5*, *KCNJ6*, *KCTD7* and *KCNQ2*) except one, namely *CACNA1S*. All transcriptomic members of solute carrier family (*SLC18A3*, *SLC5A7* and *SLC6A4*), and dopamine, glutamate, adrenergic and cholinergic receptors (*DRD5*, *GRID2*, *GRIN2A*, *GRM2*, *GRM7*, *ADRAID*, *ADRB2*, *CHRM3* and *CHRNB3*) were also elevated. Alternatively, FD reduced the expression of the transcripts associated with the cytokines (*IL1B*, *IL10*, *PRL* and *TNF*) and early growth response agents (*EGR1* and *EGR2*). The members of zinc finger family (*ZNF385B* and *ZNF423*) displayed over expression, but those of the teashirt zinc finger family (*TSHZ1* and *TSHZ2*) displayed suppressed expression in the FD-fed mice. Transcripts encoding the G-protein coupled receptor (*GPR6*) were elevated, but that encoding the ionotropic GABA receptors were differentially expressed. FD inhibited the transcripts associated with the domain of alpha 5 (*GABRA5*) and elevated alpha 4 (*GABRA4*), respectively. Although *GABRG3* and *GABRA5* are phenotypically juxtaposed in human chromosome, FD elevated the former and suppressed the later transcript.

### 3.1.ii. Nervous system development and function {#s3a2}

One hundred and fifty genes (13.13% of GOI) were associated with the "nervous system development and function" with a range of *p* values from 2.92×10^−3^ to 1.01×10^−7^ ([Table 5](#pone-0090425-t005){ref-type="table"}). Neurogenesis (Ngs) was the most enriched function; 73 transcripts represented 48.6% of all the members associated with the parent function term. Further investigation of Ngs associated genes identified five of the most significantly enriched functional sub-categories, which enlisted 62 genes representing 85% of all genes associated with Ngs. These sub-families were (i) differentiation of neurons (DoN) (30 genes, *p* = 1.7×10^−31^) ([Figure 3A](#pone-0090425-g003){ref-type="fig"}, [Table 5](#pone-0090425-t005){ref-type="table"}), (ii) growth of neurites (GoN) (29 genes, *p* = 2.3×10^−24^) ([Figure 3A](#pone-0090425-g003){ref-type="fig"}, [Table 5](#pone-0090425-t005){ref-type="table"}), (iii) differentiation of the nervous system (DNS) (29 genes, *p* = 7.6×10^−23^) ([Figure S2](#pone.0090425.s002){ref-type="supplementary-material"}, [Table 5](#pone-0090425-t005){ref-type="table"}), (iv) formation of plasma membrane projections (FPMP) (26 genes, *p* = 4.71×10^−19^) ([Figure S2](#pone.0090425.s002){ref-type="supplementary-material"}, [Table 5](#pone-0090425-t005){ref-type="table"}) and (v) neuritogenesis (Ntg) (23 genes, p = 8.02×10^−18^) ([Figure S2](#pone.0090425.s002){ref-type="supplementary-material"}, [Table 5](#pone-0090425-t005){ref-type="table"}). Among these five closely interconnected sub-families, DoN and GoN collectively enlisted the largest number of unique transcripts (50, 68.5% of the genes associated with Ngs). Therefore, we focused primarily on these two functional sub- categories ([Figure 3A](#pone-0090425-g003){ref-type="fig"}).

![Regulatory networks showing the clusters of differentially-regulated genes involved in "nervous development and functions".\
The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log~1.5~ (FD-/SD-fed mice) in the FD-fed mice compared to the SD-fed mice (a color scale is at the bottom right corner). The genes are clustered based on their proteins\' cellular locations in the nucleus, cytoplasm, plasma membrane, and extracellular space. The genes without the location information are grouped under 'unknown'. [*Figure 3A*](#pone-0090425-g003){ref-type="fig"} depicts the two top-ranked subcategories of "neurogenesis". "Differentiation of neurons" (left panel) and "growth of neurites" (right panel) enlist 30 and 29 genes with *p* values of 1.7×10^−31^ and 2.3×10^−24^, respectively. [*Figure 3B*](#pone-0090425-g003){ref-type="fig"} depicts "synaptic transmission", the most significant nervous function. It enlists 34 genes, *p* = 4.9×10^−7^.](pone.0090425.g003){#pone-0090425-g003}
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###### The genomic candidates associated with two top-ranked "nervous system development and functions": neurogenesis (Ngs) and the synaptic transmission (SyT).

![](pone.0090425.t005){#pone-0090425-t005-5}

  Entrez ID    Gene symbol   Log Ratio   Nervous system development and functions
  ----------- ------------- ----------- ------------------------------------------
  11922          NEUROD6       2.22             Ngs (Ntg, FPMP, DCNS, DoN)
  18530           PCDH8        2.12                        SyT
  211134          LZTS1        1.80               Ngs (Ntg, FPMP, DCNS)
  319922          VWC2         1.43                  Ngs (DCNS, DoN)
  56198           HEYL         1.35                     Ngs (DoN)
  21960            TNR         1.24                        SyT
  20508          SLC18A3       1.20                  Ngs (Ntg, FPMP)
  108068          GRM2         1.18                        SyT
  14618           GJB1         1.15                  Ngs (GoN, DCNS)
  18053           NGFR         1.15          Ngs (Ntg, FPMP, GoN, DCNS, DoN)
  76829           DOK5         1.13                     Ngs (GoN)
  12671           CHRM3        1.11                        SyT
  108043         CHRNB3        1.10                        SyT
  12661           CHL1         1.10             Ngs (Ntg, FPMP, DCNS, DoN)
  18216           NTSR1        1.07                        SyT
  108073          GRM7         1.05                        SyT
  20618           SNCG         1.03                        SyT
  65254          DPYSL5        1.02                     Ngs (GoN)
  140741          GPR6         1.01                     Ngs (GoN)
  12774           CCR5         0.99                     Ngs (DoN)
  110893         SLC8A3        0.98                        SyT
  14811          GRIN2A        0.98                        SyT
  16772           LAMA1        0.96                Ngs (Ntg, GoN, FPMP)
  18088          NKX2-2        0.93                  Ngs (DCNS, DoN)
  17136            MAG         0.90                Ngs (Ntg, GoN, FPMP)
  12801           CNR1         0.88             SyT, Ngs (GoN, DCNS, DoN)
  53404           ATOH7        0.85                   Ngs (GoN, DoN)
  63993          SLC5A7        0.84                        SyT
  20418           SHC3         0.80                SyT, Ngs (DCNS, DoN)
  18213           NTRK3        0.80             Ngs (Ntg, GoN, FPMP, DoN)
  15567          SLC6A4        0.80                  Ngs (DCNS, DoN)
  20665           SOX10        0.80                     Ngs (DCNS)
  19049          PPP1R1B       0.78                     Ngs (DoN)
  12570          CDK5R2        0.77                Ngs (GoN, DCNS, DoN)
  12161           BMP6         0.75                   Ngs (GoN, DoN)
  20562           SLIT1        0.74             Ngs (Ntg, GoN, FPMP, DCNS)
  21834           THRB         0.71                     Ngs (DCNS)
  22422           WNT7B        0.70                  Ngs (Ntg, FPMP)
  192167          NLGN1        0.68                   SyT, Ngs (DoN)
  230777         HCRTR1        0.67                        SyT
  16590            KIT         0.66                     Ngs (GoN)
  12286          CACNA1A       0.66             Ngs (Ntg, FPMP, DCNS, DoN)
  18081           NINJ1        0.66                     Ngs (GoN)
  22421           WNT7A        0.65                Ngs (Ntg, FPMP, DoN)
  23859           DLG2         0.64                        SyT
  17172           ASCL1        0.64             Ngs (Ntg, FPMP, DCNS, DoN)
  13616           EDN3         0.63                     Ngs (DoN)
  12005           AXIN1        0.62                     Ngs (FPMP)
  70357          KCNIP1        0.62                        SyT
  13492           DRD5         0.59                        SyT
  13796           EMX1         0.56                  Ngs (DCNS, DoN)
  11682            ALK         0.54                     Ngs (GoN)
  18125           NOS1         0.54                Ngs (Ntg, FPMP, DoN)
  319924          APBA1        0.51                        SyT
  22412           WNT9B        0.48                     Ngs (DoN)
  11555           ADRB2        0.47                SyT, Ngs (GoN, DCNS)
  22248          UNC119        0.46                        SyT
  12048          BCL2L1        0.44                  Ngs (DCNS, DoN)
  14586           GFRA2        0.39                Ngs (Ntg, GoN, FPMP)
  67903           GIPC1        0.37                        SyT
  16825           LDB1         0.37                     Ngs (DCNS)
  19697           RELA         0.34                     Ngs (GoN)
  14804           GRID2        0.32                        SyT
  18753           PRKCD        0.31                     Ngs (GoN)
  12799            CNP         0.30                SyT, Ngs (Ntg, FPMP)
  17528            MPZ         0.29             SyT, Ngs (Ntg, GoN, FPMP)
  13871           ERCC2        0.28                  Ngs (DCNS, DoN)
  18019          NFATC2        0.27                     Ngs (GoN)
  171166         MCOLN3        −0.22                    Ngs (DoN)
  241568         LRRC4C        −0.26                 Ngs (Ntg, FPMP)
  242316          GDF6         −0.28                 Ngs (FpMP, DoN)
  18126           NOS2         −0.32                    Ngs (DCNS)
  26419           MAPK8        −0.35         Ngs (Ntg, FPMP, GoN, DCNS, DoN)
  110886         GABRA5        −0.37                       SyT
  15234            HGF         −0.38         Ngs (Ntg, FPMP, GoN, DCNS, DoN)
  16870           LHX2         −0.39                 Ngs (DCNS, DoN)
  16176           IL1B         −0.44       SyT, Ngs (Ntg, FPMP, GoN, DCNS, DoN)
  19877           ROCK1        −0.61                 Ngs (GoN, FPMP)
  13654           EGR2         −0.69                    Ngs (DCNS)
  216858         KCTD11        −0.73                    Ngs (DoN)
  14173           FGF2         −0.87       SyT, Ngs (Ntg, FPMP, GoN, DCNS, DoN)
  21926            TNF         −1.21         SyT, Ngs (Ntg, GoN, FPMP, DCNS)

The neurogenesis biofunction is subsequently subcategorized into differentiation of neurons (DoN), growth of neurites (GoN), differentiation of nervous system (DNS), formation of plasma membrane projections (FPMP), and neuritogenesis (Ntg). The genes are identified by the Entrez IDs and gene symbols. The log ratio indicates the log~1.5~ transformed of the average transcriptomic expressions from FD-/SD-fed mice.

DoN and GoN shared five transcripts: *BMP6*, *CDK5R2*, *CNR1*, *NTRK3*, and *ATOH7*; all of them were elevated by FD. In addition, there were four transcripts shared by all five sub-categories; *NGFR* was elevated, and *FGF2*, *HGF* and *MAPK8* were all suppressed by FD.

Synaptic transmission (SyT) ([Figure 3B](#pone-0090425-g003){ref-type="fig"}, [Table 5](#pone-0090425-t005){ref-type="table"}) was a highly significant sub-family of nervous system development and function (34 molecules, 23.3% of parent function; *p* = 4.9×10^−7^) sharing 10 common genes with Ngs (*CNR1*, *SHC3*, *NLGN1*, *ADRB2*, *CACNA1A*, *CNP*, and *MPZ* were elevated and *TNF*, *FGF2*, and *IL1B* were suppressed by FD).

DoN, GoN and SyT enlisted 80%, 79% and 88% elevated genes, respectively. In DoN, the proteins associated with these transcripts are almost equally distributed among the extracellular space (8 genes), plasma membrane (7 genes), cytoplasm (6 genes) and nucleus (8 genes). On the other hand, proteins encoded by 48% and 71% of the transcripts associated with GoN and SyT, respectively, are localized in the plasma membrane.

FD-elevated transcripts encoding proteins are associated with a wide ensemble of transmembrane receptors and transportation functions (*SOX10*, *CHRNB3*, *GFRA2*, *NGFR*, *APBA1*, *GJB1*, *SLC18A3*, *SLC5A7*, *SLC6A4* and *SLC8A3*) and membrane-based G-protein coupled reception (*ADBR2*, *CCR5*, *CHRM3*, *CNR1*, *DRD5*, *GPR6*, *GRM2*, *GRM7*, *HCRTR1* and *NTSR1*). FD further increased the expression of most of the genes regulating transcription, such as *ASCL1*, *EMX1*, *HEYL*, *LDB1*, *LZTS1*, *NFATC2*, *NKX2-2* and *RELA*, excluding two, *EGR2* and *LHX2*. Alternatively, FD suppressed the transcripts linked to the growth factors (*FGF2*, *HGF* and *GDF6*) and the cytokines (*IL1B* and *TNF*). The transcripts regulating the protein kinases displayed a mixed expression profile; *ALK*, *DLG2*, *KIT*, *NTRK3* and *PRKCD* were elevated, but *MAPK8* and *ROCK1* were suppressed by FD.

### 3.1.iii. Apoptosis and immune response {#s3a3}

Apoptosis and immune response were the two most enriched sub-categories of "cell death" and "inflammatory response" respectively, which explained 48% and 95% of the transcripts enlisted by the respective parent terms. Together, they shared 34 genes; 23 of these were suppressed ([Table S5](#pone.0090425.s007){ref-type="supplementary-material"}).Most of the proteins encoded by these transcripts associated with apoptosis (30%) and immune response (35%) are localized in the plasma membrane.

The pool of cytokine associated transcripts (*CSF2*, *CXCL11*, *IK*, *IL10*, *IL19*, *IL1B*, *PRL*, *TNF* and *TNFSF14*) was suppressed in FD-fed mice excluding *IL25*elevated. Likewise, a large panel of CD markers excluding *CD4* was suppressed by FD. The list included *CD2*, *CD3G*, *CD80*, *CD28* and *CD7*, which are associated with T-cells; *CD5* and *CD48* are associated with B-cells; *CD244* is associated with both NK-cells and T-cells; and *CD226* is associated with platelets as well as T-cells. Alternatively, all the transcripts associated with transportation (*GJA4*, *LBP* and *SFTPA1*) were elevated. Among the growth factors, *BMP6* and *PGF* transcripts were elevated; whereas *FGF2* and *HGF* were suppressed. All of the kinase-transcripts encoding protein localized in the plasma membrane were elevated (*ALK*, *KIT* and *NTRK3*), while the rest (*CHEK1*, *MAPK8*, *PDPK1*, *PRKX* and *ROCK1*) were suppressed by FD.

3.2 Validation of gene expression by the real-time PCR analysis {#s3b}
---------------------------------------------------------------

The elevated expressions of *DRD3*, *GABRR1*, *CCKBR* and *GABRA3* encoding proteins localized in the membrane were validated by PCR array ([Figure 4](#pone-0090425-g004){ref-type="fig"}). The suppressed genes validated by qPCR included *MAOA*, *GAD1*, *HPRT1*, *NPY1R*, *CHRNA1*, *CHRNB1*, *GABRD* and *GABRG2*. The assay could not confirm the expressions of *CHRNB2*, *CHRNE*, *GABRP* and *GABRB2*.

![Regulatory networks showing clusters of differentially-regulated genes predicted by mRNA microarray and validated by 96-well qPCR assay.\
The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored panels show significantly increased and decreased expression in the FD-fed mice compared to the SD-fed mice (log~1.5~ (FD-/SD-fed mice). The right and left panels represent the mRNA microarray and qPCR output, respectively. The molecules without color are not mined by the present analysis; they are used to build the networks. These molecules constitute the major hubs of this network, but are not identified in the data shown here.](pone.0090425.g004){#pone-0090425-g004}

By using the low throughput qPCR assay ([Figure 5](#pone-0090425-g005){ref-type="fig"}), we confirmed that *FKBP5* and *NOS-1* were elevated by FD while *BDNF*, *MMP9* and *SOD1* were suppressed.

![Genomic regulation of five genes associated with physiological stress (*NOS1*, *FKBP5*, *MMP9*, *SOD1* and *BDNF*) validated by real-time PCR assay.\
The bar graph shows the genomic fold changes (FD-fed/SD-fed mice) with ± SEM. The horizontal line represents the control line depicting the fold change due to FD consumption.](pone.0090425.g005){#pone-0090425-g005}

Altogether, the qPCR assay validated 76% of the genomic expressions tested herein.

Discussion {#s4}
==========

A multitude of *in vitro* results suggests potential benefits of n-3 PUFA enriched diets typically supplemented by fish oil, but translating the knowledge to a viable therapeutic model remains challenging [@pone.0090425-Jicha1], [@pone.0090425-daSilva1], [@pone.0090425-Lesperance1], [@pone.0090425-Sublette1]--[@pone.0090425-Sarris1]. There is a necessity for a more systematic comprehension of the etiologic relationships between the fish oil and their reported effects on various illnesses.

In light of the several studies evaluating the range of the compositions of n-3/n-6 PUFA [@pone.0090425-Martins1]--[@pone.0090425-Lucas1], [@pone.0090425-Ross3], [@pone.0090425-Simopoulos2], our study focused on investigating one particular dietary supplement, namely the fish oil enriched with high n-3 PUFAs, EPA and DHA in particular. This high fat composition with a consequence of increased body mass is certainly a concern [@pone.0090425-vonAu1] that should be addressed by a more comprehensive investigation in the future. Furthermore, we investigated the effects on the hemibrains only; dietary effects on various brain sub-regions were not assessed as reported by others [@pone.0090425-LeNiculescu1]. Present study also did not attempt to quantify the shift of fatty acid levels in the brain as a result of consuming a high fat diet that investigated in past [@pone.0090425-Yu1]. The genomic profiling of the hemibarns could be further biased by the collection of the small midline structures such as thalamic and hypothalamic nuclei.

It is important to note that the present study solicited the molecular impacts of the fish oil, not the consequences of n-3 PUFA. The study was designed to critically comprehend the performances of the fish oil including its benefits and adverse effects. Therefore FD delivered more fish oil derived fatty acids (high n-3 PUFA; but sub-optimal n-6 PUFA) than the controls following many such precedents [@pone.0090425-Yon1], [@pone.0090425-Grant1]--[@pone.0090425-Woodworth1]. SD with nearly equivalent caloric contribution had unadjusted fat supplements like many other studies [@pone.0090425-Yon1], [@pone.0090425-Grant1]--[@pone.0090425-Woodworth1]. Adjusting the fatty acid presentation in the diet potentially derived from other sources, such as soybeans might alter the molecular makeups of the rodents risking confounding the outcome.

The FD contained 5.2% of n-3 PUFA and 0.65% of n-6 PUFA, presenting a ratio of 8∶1 of n-3 PUFA: n-6 PUFA; the SD contained 0.2% and 1.22% of n-3 and n-6 PUFA, respectively, with a ratio of 1∶6. By mass, FD consisted of 16% fish oil, and the total fat composition in FD was 1.5 fold higher than SD. FD contained twenty times more n-3 PUFA and 50% less n-6 PUFA as present in SD. Furthermore, FD contained a 1.5∶1 ratio of the EPA: DHA and a 7∶1 ratio of EPA: AA, which was in agreement with the literature showing health benefits [@pone.0090425-Adams1]--[@pone.0090425-Simopoulos1], [@pone.0090425-Simopoulos2], [@pone.0090425-Freeman2]. By weight, other major diet components including protein, carbohydrate, vitamins and minerals were similar in FD and SD, and the gross energy levels were also equivalent ([Table 1](#pone-0090425-t001){ref-type="table"}).

FD and SD were introduced to randomly chosen mouse groups at three weeks of age. The animals consumed their respective diets for another five months, which is equivalent to their late adolescence. Subsequently, the mice were euthanized to collect the brain samples for transcriptomic analysis.

The two mouse populations gained body weight differently. FD mice gained 18% more weight with a marginal significance (*p* = 0.06) in accordance with a previous study [@pone.0090425-Guo1]. This could possibly be a negative effect of the high lipid diet [@pone.0090425-vonAu1]; further optimization of the dietary components is required to control the weight gain and consequent health issues. It is, however, beyond the scope of the present study to discuss the potential markers associated with obesity, such as the genes associated with fatty acids (*SLC27a4*, *FADS2*, *FA2H*, and *FADS6*; all up-regulated by FD) and insulin treatment (*INSIG1* up-regulated and *IRS1*, *IGFBP2*; all down-regulated by FD) ([Table S2](#pone.0090425.s004){ref-type="supplementary-material"}).

4.1. Fish oil mediated augmentation of the brain and nervous system {#s4a}
-------------------------------------------------------------------

The functional consequences of synaptic plasticity include the power of retention and retrieval of memory; and shifting of learning and behavioral paradigms [@pone.0090425-Caroni1], [@pone.0090425-Gogolla1]. Environments combined with diets can critically modify the synaptic networks that involve formations, differentiation, repositioning, and elimination of synapse.

The NMDA receptors (NMDARs) are the critical regulators of synaptic plasticity and particularly of the long term consequences such as memory retention [@pone.0090425-Balcombe1], [@pone.0090425-Caroni1], [@pone.0090425-Sheng1], [@pone.0090425-Kotaleski1]. Src-mediated direct phosphorylation of NMDARs initiates the presynaptic influx of Ca^+2^ [@pone.0090425-Sheng1]. FD apparently activated this presynaptic pathway by elevating the key transcriptomic members, including *nSHC* (also known as *SHC3*), *NMDAR2A* (also known as *GRIN2A*) and *CACNA1A*. Promoting the excitatory against the inhibitory synaptic transmissions [@pone.0090425-Caddick1], *CACNA1A* contributes to a number of neurological disorders [@pone.0090425-Pietrobon1]. . Unlike *CACNA1A*, which closely regulates the nervous system, *CACNA1S* suppressed by FD is associated with photoreception and thermoregulation [@pone.0090425-Specht1], [@pone.0090425-Kil1].

NMDAR-mediated influx of Ca^+2^ contributes to the long term potentiation, thereby controlling the behavioral learning, fear response and extinction [@pone.0090425-Caroni1], [@pone.0090425-Kotaleski1], [@pone.0090425-DeRoo1]. Related observation of elevated *mGluR2* (*GRM2*) in FD-fed mice was rather counterintuitive. *mGluR2* in association with moderate Ca^+2^ influx is linked to long term depression [@pone.0090425-Burnashev1]. Addressing the paradox, literatures suggest that the temporal pattern of Ca^+2^ deposits may shift the consequence from depression to potentiation, and differential buffering of intracellular Ca^+2^ may also shift the balance [@pone.0090425-Sheng1]. Although we could not rule out the possibility of FD-induced long term depression, our results described hereafter increasingly favored the possibility that FD preferentially promoted long term potentiation.

Supporting the hypothesis, FD enhanced glutamatergic activity ( elevated *DRD-2/-3/-5*; *GRM-2/-7*; and *GRI-D2/-N2a* in the FD-fed mice) driving the calcium and dopamine messengers to phosphorylate the protein phosphatase 1 regulatory subunit 1B [@pone.0090425-Kotaleski1]. Elevated *PPP1R1B*, also observed by administering DHA-enriched diet [@pone.0090425-LeNiculescu1] is critically related to the emotional learning associated with long term potentiation [@pone.0090425-CurcicBlake1]. In addition, FD elevated a group of transcriptional members associated with choline influx, such as *CHRM3*, *CHRNB3* and *SLC5A*, which typically promote long term potentiation [@pone.0090425-Conner1]. FD induced elevation of *PDPK1* and *AKT* (alternate name: *PKB*), two integral downstream members of PI3K pathways, is likely to cause spine enlargement and stability, thus promoting long term potentiation maintenance [@pone.0090425-Vanhaesebroeck1].

Together, the accumulated evidence from this study increasingly linked FD to long term potentiation, as opposed to long term depression.

Emerging knowledge elucidating the complexity of BDNF activity regulation begins to dissociate BDNF from the robust synapse as suggested in past [@pone.0090425-Bousquet3]--[@pone.0090425-Kovalchuk1]. Researchers have found that the TRKB-independent pro-BDNF signaling pathway is the causative factor of compromised synapse [@pone.0090425-Zagrebelsky1], and potentially eliciting depression [@pone.0090425-Woo1]. In comparison to the remote PTSD patients, recent PTSD patients have been diagnosed with higher levels of BDNF that likely contribute to the biased consolidation of fear memory [@pone.0090425-Hauck1]. Evidently, the memory consolidation process is exon-specific. Prolonged stress applied on the rodents significantly elevated BDNF mRNA levels in exon I (35%), IV (20%) and IX (16%), and substantially elevated mRNA of exon II (20%) [@pone.0090425-Takei1]. In this context, our microarray data predicted suppressed exon II of BDNF (NM_007540, vendor-delivered information, [Table S1](#pone.0090425.s003){ref-type="supplementary-material"}) in FD-fed mice, and the qPCR assay ([Figure 5](#pone-0090425-g005){ref-type="fig"}) validated the outcome.

Conversion of pro-BDNF to mature BDNF is mediated by MMP-9, [@pone.0090425-Lee1], [@pone.0090425-Liuzzi1], which was transcriptionally suppressed by FD. Supporting evidence reported the n-3 PUFA-induced inhibition of MMP-9 in brain cells challenged by an endotoxic assault *in vitro* [@pone.0090425-Liuzzi1].

Hence, we postulate that FD promotes axonal growth by steering a BDNF-independent network critically regulated by Src to activate PI3K-AKT-PKC downstream. In fact, the independent actions of Src and BDNF have been reported in the past as a response to a dietary imbalance caused by zinc deficiency [@pone.0090425-Xu1].

4.2 Fish oil mediated neuroprotection {#s4b}
-------------------------------------

Consistent with a past study [@pone.0090425-LeNiculescu1], here we also reported a host of elevated genes in FD-fed mice associated with the myelin accumulation and preservation, including *MOG*, *MPZ* and *MAG*. Demyelinated lesions in neuronal cells are early indicators of inflammation that lead to the rapid destruction of the myelin sheath, causing increased vulnerability of the axons [@pone.0090425-Kucharova1]. In fact, selective loss of MOG was identified as a serologic marker of inflammatory brain disease [@pone.0090425-AboulEnein1].

Pro-inflammatory cytokines such as *TNF-a*, *IL-1B*, *IL-10* and *TNFSF1* showed decreased transcriptomic expression, while the transcription of interferon gamma antagonist (*IK*) was elevated by FD in accordance to many past studies [@pone.0090425-Caughey1]--[@pone.0090425-Gorjao1]. A study conducted on healthy young human adults identified the lower levels of n-3 PUFA (or a higher n-6: n-3 ratio) in serum as the primary cause of the larger influx of IFN-γ and TNF-α [@pone.0090425-KiecoltGlaser2], [@pone.0090425-Maes1]. Of particular note, we observed elevated *RELA* in FD mice; a rather counterintuitive observation, particularly in light of the suppressed expression of related genes like *TNF*, and the relevant past studies [@pone.0090425-Suk1]. One possible reason could be the near obesity condition of the FD-fed mice; a high fat diet allegedly increases NF-κB activities in rodents [@pone.0090425-Carlsen1].

The immunological implications of fish oil were further supported by the comprehensive FD induced suppression of CD markers associated with T-cells, B-cells, NK-cells and platelets. Emerging knowledge suggests that there are inhibitory effects of n-3 PUFA on CD cells, the potential markers of depression [@pone.0090425-Rizzo1].

Down-regulation of apoptotic pathways and promotion of cell survival are known implications of n-3 PUFA enriched diets. Elevated *AKT* and *BCL21A* in FD-fed mice are the established markers of cell survival [@pone.0090425-Matsuda1] [@pone.0090425-Zhang1]. The suppressed genes encoding the caspase family (*Casp -1/-4/-7/-14*) may suggested the diet\'s potential protective roles against inflammation by regulating the caspase family members [@pone.0090425-Muhie1]--[@pone.0090425-Mills1].

4.3 Potential therapeutic efficacy of FD treating neurodegenarative disorders {#s4c}
-----------------------------------------------------------------------------

The motivation of testing fish oil as the dietary supplements could be derived from the ongoing clinical trial activities evaluating the agonists of GABRG-3, GABRA-4, DRD-5, and THRB (all were elevated by FD), and the antagonists of GABRA-5 (suppressed by FD) for treating depression ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)). On the other hand, the antagonists targeting GABRG-3, GABRG-4, DRD5, ADR -A1D/--B2, CHRM-3, and SLC6A4 (all elevated by FD) are under investigation for treating bipolar disorder and schizophrenia.

In contrast, FD-regulated transcripts could be relevant in eliciting the risk of the schizophrenia, bipolar disorder, and suicidal inclination. FD, for instance activated *ADR-A1D/-B2* and *SLC6A4*; and the activated adrenergic and serotoninergic pathways are linked to augment the suicidal psychopathology [@pone.0090425-Mann1]. In addition, several of the GABA family members (*GABRG-3*, *GABRG-4*) and key dopamine receptors (*DRD5*) were also elevated by FD. The activities of GABA families and dopaminergic hyperactivity are positively correlated with the prevalence of bipolar disorder and schizophrenia [@pone.0090425-Torrey1] [@pone.0090425-MarinBivens1]. Contrastingly, dopaminergic hypoactivity has been recognized as a possible precursor of depression [@pone.0090425-Meyer1]. This observation emphasizes the fact that the efficacy of fish oil potentially depends on the disease pathophysiology.

Affective disorder is typically triggered by the decreased activities of antioxidants such as glutathione and the depletion of serological markers such as BDNF and somatostatin [@pone.0090425-Post1]. Our report showed FD-induced elevation of a number of transcripts related to transmembrane glutathione transfer (*Gstm -4/-6*, and *Gstt-1*) ([Table S2](#pone.0090425.s004){ref-type="supplementary-material"}) accompanied by *CORT* encoding cortistatin, and thereby likely activated of the somatostatin receptors. Among other neurodegenerative diseases, the reported impacts of FD on AD and PD were in accordance with a multitude of existing evidence [@pone.0090425-Hooijmans1], [@pone.0090425-Jicha1], [@pone.0090425-daSilva1], [@pone.0090425-Bousquet2]. FD suppressed *APBA1*, a key gene encoding the amyloid beta (A4) precursor protein-binding family; thereby potentially suppressed the amyloidal toxicity, a vital precursor of AD progression [@pone.0090425-Lorenzo1]. Possible activation of the dopaminergic cascade, evident from the elevated receptors (*DRD-2/-3/-5*), indicated a stronger efficacy of FD in treating PD.

In addition, FD altered a collection of transcriptomic expression linked to AD and PD onset [@pone.0090425-Blandini1], [@pone.0090425-McGeer1], such as *NOS-2*, *SOD1* and caspases (*CASP-1/-4/-7*). Accumulated evidences underscore the importance of the beta-adrenergic receptors and MAPK signaling towards AD pathology [@pone.0090425-Wang1]; members of these respective networks (*ADR-A1D/-B2* and *MAPK-8*) were altered by FD.

FD mice showed a comprehensive elevation of the transcripts associated with voltage-gated potassium channels (*KCNMB3*, *KCNQ5*, *KCN1P1*, *KCNC4*, *KCNC3*, *KCNA5*, *KCNJ6*, *KCTD7* and *KCNQ2*) and cholinergic modulation (*CHRM3 and CHRNB3*), which are associated with memory consolidation and stress management [@pone.0090425-Heck1]--[@pone.0090425-Takuma1]. Among another psychological illnesses, FD showed positive implications in PTSD, regulating some of the potential therapeutic markers like *BDNF*, *FKBP5* and *SLC6A4* [@pone.0090425-Kolassa1] ([Table 2](#pone-0090425-t002){ref-type="table"}). In addition, [Table 2](#pone-0090425-t002){ref-type="table"} shows a list of psychological debilities associated with a panel of transcripts investigated by qPCR.

Conclusions {#s5}
===========

The biomechanisms exhibited by the fish oil that facilitate neurotrophic regulation are still elusive. The knowledge gap limits our predictive aptitude in realistically estimating the efficacy of this dietary supplement. To address this challenge, we customized a diet enriched of 16% fish oil by weight, the optimum fraction of oil added to the rodent food without altering its texture from the standard lab diet. Two randomly chosen groups of C57BL/6J mice consumed one of the two diets from weaning age until their young adulthood. We sacrificed five month old mice and investigated their hemibrains using a genome-wide transcriptomic platform.

Functional analyses of the transcriptomic data focused on the areas of the *neurogenesis, neuroviability and neurodegenerative disorders.* The GOI were clustered into four most significant functions: "Neurological disease", "Nervous system development and function", "Immune response" and "Apoptosis". Together these functions encompassed 247 transcripts (∼20%) identified from 1,142 genes displaying the most differential expression between the FD- and SD-fed mice. Approximately 40% of the proteins associated with these genes are located in the plasma membrane, suggesting a biased impact of the fish oil on the membrane-associated activities. Leveraging from the mouse brain atlas (mouse.brain-map.org) we found several of these genes found enriching the brain regions ([Table S4](#pone.0090425.s006){ref-type="supplementary-material"}) such as olfactory bulb, cerebellar cortex, thalamus and amygdala typically associated with the motor activities, information relay and neuropsychology.

In FD-fed mice, a Src-mediated calcium-controlled network was suggested to reinforce synapse that possibly operated in a BDNF-MMP-9 independent pathway. FD suppressed the transcription of BDNF exons II, which is known to express in response to stress [@pone.0090425-Takei1]. Activated PI3K-AKT-PKC cascades operated in concert. We further acknowledged a risk of spurring depression through FD-mediated activation of mGluR2/Ca^+2^ [@pone.0090425-Burnashev1]. However, the FD-induced long term potentiation was deemed as more plausible endpoint in cognition of the additional evidences, including the stimulation of NMDAR and downstream glutaminergic/dopaminergic/cholinergic networks [@pone.0090425-Kotaleski1], [@pone.0090425-Conner1] and the elevated transcription of WNT family genes [@pone.0090425-Gogolla2], *PPP1R1B* [@pone.0090425-CurcicBlake1] and *NEUROD6* [@pone.0090425-Uittenbogaard1]. The risk of Ca^+2^ -induced biased recurrence of excitatory synaptic transmission was possibly mitigated by the FD-induced *NLGN1* that typically helps in restoring the balance between the excitatory and inhibitory synapses [@pone.0090425-Prange1].

FD-induced attenuation of oxidative stress and reduction of amyloidal burden coupled with suppressed inflammatory and apoptosis networks affirmed the potential efficacy of fish oil in treating a range of neurodegenerative debilities such as affective, Alzheimer\'s and Parkinson\'s disorders. In contrast, the FD-stimulated neuromodulators like dopamine, choline, GABA and glutamate may diminish the efficacy of the fish oil in treating bipolar disorder, schizophrenia and suicidal inclination, which has been proposed to be triggered by the hyperactivity of the same pool of molecular messengers [@pone.0090425-Torrey1], [@pone.0090425-MarinBivens1]. Taken together, our results suggested a potential susceptibility of the fish oil\'s efficacy on the disease pathology and highlighted the need for strategic repositioning of the fish oil as a therapeutic adjuvant. Supporting our results a number of past in vitro rodent models [@pone.0090425-Puskas1] [@pone.0090425-Kitajka1] [@pone.0090425-BarceloCoblijn1], [@pone.0090425-Harbeby1], [@pone.0090425-Kitajka2], [@pone.0090425-Begg1] reported n-3 PUFA benefits in the restoration of myelin sheath, activation of dopaminergic networks with downstream elevation of *PPP1R1B*, activation of synaptic plasticity and comprehensive attenuation of inflammasome networks.

In conclusion, fish oil could provide therapeutic benefits for a number of neurodegenerative diseases, while there is a valid concern about its therapeutic efficacy in treating certain other illnesses. The comprehensive investigation to confirm these findings are exigent and the effectiveness of this fish oil diet should be validated by introducing this diet type to specific disease models.
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**The volcano plot of the GOI depicting the expression distribution in FD and SD fed murine hemibrains.** Here the x-axis depicts the log~2~(fold change) and y-axis depicts -log~10~(*p*-value), where p-value is calculated by FDR algorithm. The red and green dots represent the up- and down-regulated transcripts, respectively.

(TIF)
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Click here for additional data file.

###### 

**Regulatory networks showing an additional three clusters of differentially-regulated genes involved in "neurogenesis".** The nodes represent the genes and the solid lines depict the interactions between two molecules. Red- and green-colored genes show significantly increased and decreased expression (log~1.5~ (FD-/SD-fed mice) in the FD-fed mice compared to the SD-fed mice (a color scale is at the bottom right corner). The genes are clustered based on their proteins\' cellular locations in the nucleus, cytoplasm, plasma membrane, and extracellular space. Three subgroups are "differentiation of nervous system" (left panel), "formation of plasma membrane projections" (middle panel) and "neuritogenesis" (right panel). They enlist 29, 26, and 23 genes with *p* values of 7.6×10^−23^, 4.71×10^−19^ and 8.02×10^−18^, respectively.
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**List of primers and probes used in qPCR assay.**
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###### 

**List of 1,142 genes of interest (GOI).** The genes are identified by the Gene Name and gene symbol. The log ratio indicates the log~1.5~ transformed of the average transcriptomic expressions from FD-/SD-fed mice.
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Click here for additional data file.
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**Complete list of biofunction categories enriched by 1,142 genes.** For individual functional categories, corresponding range of *p* values and the number of enriching genomic members are reported.
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Click here for additional data file.
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**The brain regions enriched by the genes mined by present study relevant to "Neurological disease", "Nervous system development and function", "Inflammatory response" and "Cell death".**

(DOCX)
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Click here for additional data file.

###### 

**The genomic candidates associated with apoptosis (Apop) and immune response (ImRes).** The genes are identified by the Entrez IDs and gene symbols. The log ratio indicates the log~1.5~ transformed of the average transcriptomic expressions from FD-/SD-fed mice.
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###### 

Click here for additional data file.
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